{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:31:20Z","timestamp":1791261080104,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s11095-022-03184-3","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T20:28:06Z","timestamp":1644524886000},"page":"2745-2759","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Susceptibility of Lung Carcinoma Cells to Nanostructured Lipid Carrier of ARV-825, a BRD4 Degrading Proteolysis Targeting Chimera"],"prefix":"10.1007","volume":"39","author":[{"given":"Richa","family":"Vartak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Saraswat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketan","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"issue":"3","key":"3184_CR1","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.21037\/jtd.2020.03.11","volume":"12","author":"B Cheng","year":"2020","unstructured":"Cheng B, Xiong S, Li C, Liang H, Zhao Y, Li J, et al. An annual review of the remarkable advances in lung cancer clinical research in 2019. J Thorac Dis. 2020;12(3):1056\u201369.","journal-title":"J Thorac Dis"},{"key":"3184_CR2","doi-asserted-by":"crossref","unstructured":"Saltos A, Shafique M, Chiappori A. Update on the biology, management, and treatment of small cell lung cancer (SCLC). Frontiers in Oncology. 2020;10.","DOI":"10.3389\/fonc.2020.01074"},{"issue":"1","key":"3184_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccm.2019.10.001","volume":"41","author":"BC Bade","year":"2020","unstructured":"Bade BC, Cruz CSD. Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med. 2020;41(1):1\u201324.","journal-title":"Clin Chest Med"},{"key":"3184_CR4","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2217\/nnm.11.151","volume":"7","author":"BJ Tan","year":"2012","unstructured":"Tan BJ, Liu Y, Chang KL, Lim BK, Chiu GN. Perorally active nanomicellar formulation of quercetin in the treatment of lung cancer. Int J Nanomedicine. 2012;7:651\u201361.","journal-title":"Int J Nanomedicine"},{"issue":"2","key":"3184_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nrclinonc.2014.225","volume":"12","author":"R Rosell","year":"2015","unstructured":"Rosell R, Karachaliou N. Optimizing lung cancer treatment approaches. Nat Rev Clin Oncol. 2015;12(2):75\u20136.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"3184_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jsps.2017.10.012","volume":"26","author":"SAA Rizvi","year":"2018","unstructured":"Rizvi SAA, Saleh AM. Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J. 2018;26(1):64\u201370.","journal-title":"Saudi Pharm J"},{"issue":"1","key":"3184_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1158\/2159-8290.CD-17-0605","volume":"8","author":"A Stathis","year":"2018","unstructured":"Stathis A, Bertoni F. BET proteins as targets for anticancer treatment. Cancer Discov. 2018;8(1):24\u201336.","journal-title":"Cancer Discov"},{"issue":"9","key":"3184_CR8","first-page":"5728","volume":"11","author":"Q Lu","year":"2019","unstructured":"Lu Q, Ding X, Huang T, Zhang S, Li Y, Xu L, et al. BRD4 degrader ARV-825 produces long-lasting loss of BRD4 protein and exhibits potent efficacy against cholangiocarcinoma cells. Am J Transl Res. 2019;11(9):5728\u201339.","journal-title":"Am J Transl Res"},{"issue":"1","key":"3184_CR9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1073\/pnas.1422165112","volume":"112","author":"MG Baratta","year":"2015","unstructured":"Baratta MG, Schinzel AC, Zwang Y, Bandopadhayay P, Bowman-Colin C, Kutt J, et al. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc Natl Acad Sci. 2015;112(1):232\u20137.","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"3184_CR10","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904\u201317.","journal-title":"Cell"},{"key":"3184_CR11","doi-asserted-by":"crossref","unstructured":"Alqahtani A, Choucair K, Ashraf M, Hammouda DM, Alloghbi A, Khan T, et al. Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy. Future science OA. 2019;5(3):FSO372.","DOI":"10.4155\/fsoa-2018-0115"},{"key":"3184_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00885-3","volume":"13","author":"X Li","year":"2020","unstructured":"Li X, Song Y. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy. J Hematol Oncol. 2020;13:1\u201314.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"3184_CR13","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1038\/leu.2016.393","volume":"31","author":"DT Saenz","year":"2017","unstructured":"Saenz DT, Fiskus W, Qian Y, Manshouri T, Rajapakshe K, Raina K, et al. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells. Leukemia. 2017;31(9):1951\u201361.","journal-title":"Leukemia"},{"issue":"26","key":"3184_CR14","doi-asserted-by":"publisher","first-page":"7124","DOI":"10.1073\/pnas.1521738113","volume":"113","author":"K Raina","year":"2016","unstructured":"Raina K, Lu J, Qian Y, Altieri M, Gordon D, Rossi AMK, et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc Natl Acad Sci. 2016;113(26):7124\u20139.","journal-title":"Proc Natl Acad Sci"},{"issue":"9","key":"3184_CR15","first-page":"5728","volume":"11","author":"Q Lu","year":"2019","unstructured":"Lu Q, Ding X, Huang T, Zhang S, Li Y, Xu L, et al. BRD4 degrader ARV-825 produces long-lasting loss of BRD4 protein and exhibits potent efficacy against cholangiocarcinoma cells. American journal of translational research. 2019;11(9):5728.","journal-title":"American journal of translational research"},{"issue":"18","key":"3184_CR16","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.2217\/nnm-2020-0156","volume":"15","author":"A Saraswat","year":"2020","unstructured":"Saraswat A, Patki M, Fu Y, Barot S, Dukhande VV, Patel K. Nanoformulation of PROteolysis TArgeting Chimera targeting \u2018undruggable\u2019c-Myc for the treatment of pancreatic cancer. Nanomedicine. 2020;15(18):1761\u201377.","journal-title":"Nanomedicine"},{"key":"3184_CR17","doi-asserted-by":"crossref","unstructured":"Spriano F, Stathis A, Bertoni F. Targeting BET bromodomain proteins in cancer: The example of lymphomas. Pharmacology & Therapeutics. 2020:107631.","DOI":"10.1016\/j.pharmthera.2020.107631"},{"issue":"4","key":"3184_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.bioeng.2006.05.026","volume":"23","author":"DF Emerich","year":"2006","unstructured":"Emerich DF, Thanos CG. The pinpoint promise of nanoparticle-based drug delivery and molecular diagnosis. Biomol Eng. 2006;23(4):171\u201384.","journal-title":"Biomol Eng"},{"issue":"14","key":"3184_CR19","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2217\/nnm-2020-0475","volume":"16","author":"R Vartak","year":"2021","unstructured":"Vartak R, Patil SM, Saraswat A, Patki M, Kunda NK, Patel K. Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment in vitro. Nanomedicine. 2021;16(14):1187\u2013202.","journal-title":"Nanomedicine"},{"key":"3184_CR20","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.biopha.2018.04.055","volume":"103","author":"A Khosa","year":"2018","unstructured":"Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother. 2018;103:598\u2013613.","journal-title":"Biomed Pharmacother"},{"issue":"1\u20132","key":"3184_CR21","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ijpharm.2017.04.078","volume":"526","author":"K Bhise","year":"2017","unstructured":"Bhise K, Kashaw SK, Sau S, Iyer AK. Nanostructured lipid carriers employing polyphenols as promising anticancer agents: quality by design (QbD) approach. Int J Pharm. 2017;526(1\u20132):506\u201315.","journal-title":"Int J Pharm"},{"issue":"2","key":"3184_CR22","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.colsurfb.2007.06.011","volume":"60","author":"H Yuan","year":"2007","unstructured":"Yuan H, Wang L-L, Du Y-Z, You J, Hu F-Q, Zeng S. Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification. Colloids Surf, B. 2007;60(2):174\u20139.","journal-title":"Colloids Surf, B"},{"key":"3184_CR23","doi-asserted-by":"crossref","unstructured":"Rathod D, Fu Y, Patel K. BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: preformulation studies, formulation development and in vitro evaluation. European Journal of Pharmaceutical Sciences. 2019;138:105039.","DOI":"10.1016\/j.ejps.2019.105039"},{"key":"3184_CR24","doi-asserted-by":"crossref","unstructured":"Vartak R, Patki M, Menon S, Jablonski J, Mediouni S, Fu Y, et al. \u03b2-cyclodextrin polymer\/Soluplus\u00ae encapsulated Ebselen ternary complex (E\u03b2polySol) as a potential therapy for vaginal candidiasis and pre-exposure prophylactic for HIV. International Journal of Pharmaceutics. 2020;589:119863.","DOI":"10.1016\/j.ijpharm.2020.119863"},{"issue":"7","key":"3184_CR25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/cac2.12040","volume":"40","author":"Y Yang","year":"2020","unstructured":"Yang Y, Ji N, Cai CY, Wang JQ, Lei ZN, Teng QX, et al. Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor. Cancer Commun. 2020;40(7):285\u2013300.","journal-title":"Cancer Commun"},{"issue":"4","key":"3184_CR26","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/cr.2016.31","volume":"26","author":"X Huang","year":"2016","unstructured":"Huang X, Dixit VM. Drugging the undruggables: exploring the ubiquitin system for drug development. Cell Res. 2016;26(4):484\u201398.","journal-title":"Cell Res"},{"issue":"12","key":"3184_CR27","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.3390\/ijms21124325","volume":"21","author":"IZ Uras","year":"2020","unstructured":"Uras IZ, Moll HP, Casanova E. Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future. Int J Mol Sci. 2020;21(12):4325.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"3184_CR28","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1021\/acschembio.5b00216","volume":"10","author":"M Zengerle","year":"2015","unstructured":"Zengerle M, Chan K-H, Ciulli A. Selective small molecule induced degradation of the BET bromodomain protein BRD4. ACS Chem Biol. 2015;10(8):1770\u20137.","journal-title":"ACS Chem Biol"},{"issue":"36","key":"3184_CR29","doi-asserted-by":"publisher","first-page":"22840","DOI":"10.1021\/acsomega.0c02072","volume":"5","author":"J-Y Wang","year":"2020","unstructured":"Wang J-Y, Song Y-Q, Peng J, Luo H-L. Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy. ACS Omega. 2020;5(36):22840\u20136.","journal-title":"ACS Omega"},{"issue":"3","key":"3184_CR30","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3109\/21691401.2013.801848","volume":"42","author":"C Han","year":"2014","unstructured":"Han C, Li Y, Sun M, Liu C, Ma X, Yang X, et al. Small peptide-modified nanostructured lipid carriers distribution and targeting to EGFR-overexpressing tumor in vivo. Artificial cells, nanomedicine, and biotechnology. 2014;42(3):161\u20136.","journal-title":"Artificial cells, nanomedicine, and biotechnology"},{"issue":"2","key":"3184_CR31","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.colsurfb.2010.06.008","volume":"80","author":"L Jia","year":"2010","unstructured":"Jia L, Zhang D, Li Z, Duan C, Wang Y, Feng F, et al. Nanostructured lipid carriers for parenteral delivery of silybin: Biodistribution and pharmacokinetic studies. Colloids Surf, B. 2010;80(2):213\u20138.","journal-title":"Colloids Surf, B"},{"issue":"1\u20132","key":"3184_CR32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ijpharm.2017.04.076","volume":"526","author":"C Tetyczka","year":"2017","unstructured":"Tetyczka C, Griesbacher M, Absenger-Novak M, Fr\u00f6hlich E, Roblegg E. Development of nanostructured lipid carriers for intraoral delivery of domperidone. Int J Pharm. 2017;526(1\u20132):188\u201398.","journal-title":"Int J Pharm"},{"issue":"1","key":"3184_CR33","first-page":"63","volume":"12","author":"RM Khalil","year":"2013","unstructured":"Khalil RM, Abd El-Bary A, Kassem MA, Ghorab MM, Basha M. Influence of formulation parameters on the physicochemical properties of meloxicam-loaded solid lipid nanoparticles. Egyptian Pharmaceutical Journal. 2013;12(1):63.","journal-title":"Egyptian Pharmaceutical Journal"},{"issue":"1","key":"3184_CR34","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1208\/s12249-011-9727-6","volume":"13","author":"K Patel","year":"2012","unstructured":"Patel K, Padhye S, Nagarsenker M. Duloxetine HCl lipid nanoparticles: preparation, characterization, and dosage form design. AAPS PharmSciTech. 2012;13(1):125\u201333.","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"3184_CR35","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1166\/jnn.2016.11667","volume":"16","author":"E Winter","year":"2016","unstructured":"Winter E, Pizzol CD, Locatelli C, Crezkynski-Pasa TB. Development and evaluation of lipid nanoparticles for drug delivery: Study of toxicity in vitro and in vivo. J Nanosci Nanotechnol. 2016;16(2):1321\u201330.","journal-title":"J Nanosci Nanotechnol"},{"issue":"4","key":"3184_CR36","doi-asserted-by":"publisher","first-page":"288","DOI":"10.4103\/1735-5362.235156","volume":"13","author":"P Ghasemiyeh","year":"2018","unstructured":"Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages. Research in pharmaceutical sciences. 2018;13(4):288.","journal-title":"Research in pharmaceutical sciences"},{"key":"3184_CR37","doi-asserted-by":"crossref","unstructured":"Burslem GM, Smith BE, Lai AC, Jaime-Figueroa S, McQuaid DC, Bondeson DP, et al. The advantages of targeted protein degradation over inhibition: an RTK case study. Cell chemical biology. 2018;25(1):67\u201377. e3.","DOI":"10.1016\/j.chembiol.2017.09.009"},{"issue":"8","key":"3184_CR38","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrc3775","volume":"14","author":"Z Chen","year":"2014","unstructured":"Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535\u201346.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3184_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40360-018-0284-4","volume":"20","author":"X Wang","year":"2019","unstructured":"Wang X, Decker CC, Zechner L, Krstin S, Wink M. In vitro wound healing of tumor cells: inhibition of cell migration by selected cytotoxic alkaloids. BMC Pharmacol Toxicol. 2019;20(1):1\u201312.","journal-title":"BMC Pharmacol Toxicol"},{"key":"3184_CR40","doi-asserted-by":"crossref","unstructured":"Yang X. Clonogenic assay. Bio-protocol. 2012;2(10):e187-e.","DOI":"10.21769\/BioProtoc.187"},{"issue":"5","key":"3184_CR41","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/15384047.2018.1423923","volume":"19","author":"Z Gao","year":"2018","unstructured":"Gao Z, Yuan T, Zhou X, Ni P, Sun G, Li P, et al. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression. Cancer Biol Ther. 2018;19(5):407\u201315.","journal-title":"Cancer Biol Ther"},{"issue":"5","key":"3184_CR42","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1021\/acs.bioconjchem.9b00136","volume":"30","author":"A Tchoryk","year":"2019","unstructured":"Tchoryk A, Taresco V, Argent RH, Ashford M, Gellert PR, Stolnik S, et al. Penetration and uptake of nanoparticles in 3D tumor spheroids. Bioconjug Chem. 2019;30(5):1371\u201384.","journal-title":"Bioconjug Chem"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-022-03184-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-022-03184-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-022-03184-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T03:07:58Z","timestamp":1667531278000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-022-03184-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,10]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["3184"],"URL":"https:\/\/doi.org\/10.1007\/s11095-022-03184-3","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,10]]},"assertion":[{"value":"28 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interests"}}]}}